Our company

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology.
Our company focuses on the development of products for treatment of metabolic diseases and various immuno-therapies.


- BioLingus in list of "Top 20 Most Influential Companies" from CEO Insight
- Two prestigious awards from CEO Monthly Magazine 2017
- For the second time, BioLingus has been awarded the "GAMECHANGER AWARD" from the ACQ 2017 Global Awards Program.
- BioLingus wins Best Delivery System Award from the Global Health & Packaging magazine


OCT 2017

BioLingus in list of "Top 20 Most Influential Companies" from CEO Insight.

[Read More]

JUL 2017

Best European CEO Biotech – Europe
Most Innovative Biotech company – Europe
[Read More]



The Cytokine Stabilisation and Slow Release (CSSR) technology is the "mother" of the BioLingus technologies.


Through advanced "bio-engineering", the BioLingus SEED Technology is mimicking what is happening in nature in a plant SEED.


The OPUS (Oral Peptide Utility System) is our technology application to orally (sublingually) or via the mucosum administer peptides which have no immunomodulatory mode of action.


Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno therapy.

Corporate Partnerships

Corporate Partnerships

To further exploit the potential of the BioLingus Technology, we are interested in exploring partnerships with other pharmaceutical companies. Aside from pharmaceutical companies, we are also interested in working with animal health companies" (with adjusted formulations) and food companies working on innovative food supplements.

Together we unlock the potential of the BioLingus Technology, and thus transform current standard practices in the administration of peptides and proteins.


Main Office
BioLingus AG

Grossmatt 6
CH-6052 Hergiswil NW